{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T17:10:05Z","timestamp":1756487405725,"version":"3.44.0"},"reference-count":93,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128229514"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/b978-0-12-822951-4.00042-4","type":"book-chapter","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T01:25:48Z","timestamp":1719537948000},"page":"351-364","source":"Crossref","is-referenced-by-count":0,"title":["Principles of novel cellular and molecular cardiovascular therapeutics"],"prefix":"10.1016","author":[{"given":"Marta","family":"Furtado","sequence":"first","affiliation":[]},{"given":"Marta","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Sandra","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"M.","family":"Carmo-Fonseca","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/B978-0-12-822951-4.00042-4_bib1","first-page":"2982","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol 10.1016\/J.JACC.2020.11.010"},{"issue":"5769","key":"10.1016\/B978-0-12-822951-4.00042-4_bib2","first-page":"1880","article-title":"Stem cells and their niches","volume":"311","author":"Moore","year":"2006","journal-title":"Science 10.1126\/SCIENCE.1110542"},{"issue":"8","key":"10.1016\/B978-0-12-822951-4.00042-4_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm0898-929","article-title":"Regenerating functional myocardium: improved performance after skeletal myoblast transplantation","volume":"4","author":"Taylor","year":"1998","journal-title":"Nat Med 10.1038\/nm0898-929"},{"issue":"6829","key":"10.1016\/B978-0-12-822951-4.00042-4_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/35070587","article-title":"Bone marrow cells regenerate infarcted myocardium","volume":"410","author":"Orlic","year":"2001","journal-title":"Nature 10.1038\/35070587"},{"issue":"15","key":"10.1016\/B978-0-12-822951-4.00042-4_bib5","first-page":"1913","article-title":"Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans","volume":"106","author":"Strauer","year":"2002","journal-title":"Circulation 10.1161\/01.CIR.0000034046.87607.1C"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib6","first-page":"95","article-title":"A time to press reset and regenerate cardiac stem cell biology","volume":"4","author":"Epstein","year":"2019","journal-title":"JAMA Cardiol 10.1001\/JAMACARDIO.2018.4435"},{"issue":"9","key":"10.1016\/B978-0-12-822951-4.00042-4_bib7","article-title":"Efficacy and safety of stem cell therapy in advanced heart failure patients: a systematic review with a meta-analysis of recent trials between 2017 and 2019","volume":"11","author":"Jayaraj","year":"2019","journal-title":"Cureus 10.7759\/CUREUS.5585"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/stem.269","article-title":"Mesenchymal stromal cells: current understanding and clinical status","volume":"28","author":"Salem","year":"2010","journal-title":"Stem Cell 10.1002\/STEM.269"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib9","first-page":"1","article-title":"Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress","volume":"11","author":"Wu","year":"2020","journal-title":"Stem Cell Res Ther 10.1186\/S13287-020-01855-9"},{"issue":"7790","key":"10.1016\/B978-0-12-822951-4.00042-4_bib10","first-page":"405","article-title":"An acute immune response underlies the benefit of cardiac stem cell therapy","volume":"577","author":"Vagnozzi","year":"2019","journal-title":"Nature 10.1038\/s41586-019-1802-2"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib11","first-page":"1","article-title":"Therapeutic features and updated clinical trials of mesenchymal stem cell (MSC)-derived exosomes","volume":"10","author":"Lee","year":"2021","journal-title":"J Clin Med 10.3390\/JCM10040711"},{"key":"10.1016\/B978-0-12-822951-4.00042-4_bib12","first-page":"793","article-title":"Small things matter: relevance of MicroRNAs in cardiovascular disease","volume":"11","author":"Peters","year":"2020","journal-title":"Front Physiol 10.3389\/FPHYS.2020.00793"},{"issue":"5","key":"10.1016\/B978-0-12-822951-4.00042-4_bib13","first-page":"606","article-title":"Exosomes as critical agents of cardiac regeneration triggered by cell therapy","volume":"2","author":"Ibrahim","year":"2014","journal-title":"Stem Cell Rep 10.1016\/J.STEMCR.2014.04.006"},{"issue":"9","key":"10.1016\/B978-0-12-822951-4.00042-4_bib14","first-page":"911","article-title":"Isolation and expansion of adult cardiac stem cells from human and murine heart","volume":"95","author":"Messina","year":"2004","journal-title":"Circ Res 10.1161\/01.RES.0000147315.71699.51"},{"issue":"5","key":"10.1016\/B978-0-12-822951-4.00042-4_bib15","first-page":"1","article-title":"Exosomal miR-25-3p from mesenchymal stem cells alleviates myocardial infarction by targeting pro-apoptotic proteins and EZH2","volume":"11","author":"Peng","year":"2020","journal-title":"Cell Death Dis 10.1038\/s41419-020-2545-6"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib16","first-page":"209","article-title":"Enhanced cardioprotection by human endometrium mesenchymal stem cells driven by exosomal MicroRNA-21","volume":"6","author":"Wang","year":"2017","journal-title":"Stem Cells Transl Med 10.5966\/SCTM.2015-0386"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib17","first-page":"332","article-title":"Stem cell research as innovation: expanding the ethical and policy conversation","volume":"38","author":"Dresser","year":"2010","journal-title":"J Law Med Ethics 10.1111\/j.1748-720X.2010.00492.x"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib18","first-page":"115","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2016","journal-title":"Nat Rev Drug Discov 10.1038\/nrd.2016.245"},{"issue":"7504","key":"10.1016\/B978-0-12-822951-4.00042-4_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature13233","article-title":"Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts","volume":"510","author":"Chong","year":"2014","journal-title":"Nature 10.1038\/NATURE13233"},{"issue":"7","key":"10.1016\/B978-0-12-822951-4.00042-4_bib20","first-page":"597","article-title":"Human embryonic stem cell\u2013derived cardiomyocytes restore function in infarcted hearts of non-human primates","volume":"36","author":"Liu","year":"2018","journal-title":"Nat Biotechnol 10.1038\/nbt.4162"},{"issue":"7625","key":"10.1016\/B978-0-12-822951-4.00042-4_bib21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nature19815","article-title":"Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts","volume":"538","author":"Shiba","year":"2016","journal-title":"Nature 10.1038\/nature19815"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib22","first-page":"429","article-title":"Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction","volume":"71","author":"Menasch\u00e9","year":"2018","journal-title":"J Am Coll Cardiol 10.1016\/J.JACC.2017.11.047"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib23","first-page":"566","article-title":"Targeted disruption of HLA genes via CRISPR-cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell 10.1016\/J.STEM.2019.02.005"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib24","first-page":"285","article-title":"Cardiac cell therapy: current status, challenges and perspectives","volume":"113","author":"Menasch\u00e9","year":"2020","journal-title":"Arch Cardiovasc Dis. 10.1016\/J.ACVD.2020.01.002"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib25","first-page":"375","article-title":"Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors","volume":"142","author":"Ieda","year":"2010","journal-title":"Cell 10.1016\/J.CELL.2010.07.002"},{"issue":"7400","key":"10.1016\/B978-0-12-822951-4.00042-4_bib26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature11044","article-title":"In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes","volume":"485","author":"Qian","year":"2012","journal-title":"Nature 10.1038\/NATURE11044"},{"issue":"7400","key":"10.1016\/B978-0-12-822951-4.00042-4_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature11139","article-title":"Heart repair by reprogramming non-myocytes with cardiac transcription factors","volume":"485","author":"Song","year":"2012","journal-title":"Nature 10.1038\/NATURE11139"},{"issue":"14","key":"10.1016\/B978-0-12-822951-4.00042-4_bib28","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1073\/pnas.1301019110","article-title":"Reprogramming of human fibroblasts toward a cardiac fate","volume":"110","author":"Nam","year":"2013","journal-title":"Proc Natl Acad Sci USA 10.1073\/PNAS.1301019110"},{"issue":"31","key":"10.1016\/B978-0-12-822951-4.00042-4_bib29","doi-asserted-by":"crossref","first-page":"12667","DOI":"10.1073\/pnas.1304053110","article-title":"Induction of human cardiomyocyte-like cells from fibroblasts by defined factors","volume":"110","author":"Wada","year":"2013","journal-title":"Proc Natl Acad Sci USA 10.1073\/PNAS.1304053110"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib30","first-page":"235","article-title":"Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state","volume":"1","author":"Fu","year":"2013","journal-title":"Stem Cell Rep 10.1016\/J.STEMCR.2013.07.005"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib31","first-page":"1","article-title":"Cardiac regeneration by direct reprogramming in this decade and beyond","volume":"41","author":"Yamakawa","year":"2021","journal-title":"Inflamm Regen 10.1186\/S41232-021-00168-5"},{"key":"10.1016\/B978-0-12-822951-4.00042-4_bib32","first-page":"2123","article-title":"Overexpression of Gata4, Mef2c, and Tbx5 generates induced cardiomyocytes via direct reprogramming and rare fusion in the heart","author":"Isomi","year":"2021","journal-title":"Circulation 10.1161\/CIRCULATIONAHA.120.052799"},{"issue":"9","key":"10.1016\/B978-0-12-822951-4.00042-4_bib33","first-page":"1013","article-title":"Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails","volume":"25","author":"Fu","year":"2015","journal-title":"Cell Res 10.1038\/CR.2015.99"},{"issue":"6290","key":"10.1016\/B978-0-12-822951-4.00042-4_bib34","first-page":"1216","article-title":"Conversion of human fibroblasts into functional cardiomyocytes by small molecules","volume":"352","author":"Cao","year":"2016","journal-title":"Science 10.1126\/SCIENCE.AAF1502"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib35","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1073\/pnas.1214608110","article-title":"Cardiomyocyte proliferation contributes to heart growth in young humans","volume":"110","author":"Mollova","year":"2013","journal-title":"Proc Natl Acad Sci USA 10.1073\/PNAS.1214608110"},{"issue":"7","key":"10.1016\/B978-0-12-822951-4.00042-4_bib36","first-page":"1566","article-title":"Dynamics of cell generation and turnover in the human heart","volume":"161","author":"Bergmann","year":"2015","journal-title":"Cell 10.1016\/J.CELL.2015.05.026"},{"issue":"6342","key":"10.1016\/B978-0-12-822951-4.00042-4_bib37","first-page":"1035","article-title":"Cardiac regeneration strategies: staying young at heart","volume":"356","author":"Tzahor","year":"2017","journal-title":"Science 10.1126\/SCIENCE.AAM5894"},{"issue":"5","key":"10.1016\/B978-0-12-822951-4.00042-4_bib38","first-page":"729","article-title":"Building and re-building the heart by cardiomyocyte proliferation","volume":"143","author":"Foglia","year":"2016","journal-title":"Development 10.1242\/DEV.132910"},{"issue":"14","key":"10.1016\/B978-0-12-822951-4.00042-4_bib39","doi-asserted-by":"crossref","first-page":"7720","DOI":"10.3390\/ijms22147720","article-title":"Induced cardiomyocyte proliferation: a promising approach to cure heart failure","volume":"22","author":"Salama","year":"2021","journal-title":"Int J Mol Sci 10.3390\/IJMS22147720"},{"issue":"7675","key":"10.1016\/B978-0-12-822951-4.00042-4_bib40","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature24045","article-title":"Hippo pathway deficiency reverses systolic heart failure after infarction","volume":"550","author":"Leach","year":"2017","journal-title":"Nature 10.1038\/nature24045"},{"key":"10.1016\/B978-0-12-822951-4.00042-4_bib41","first-page":"24","article-title":"Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease association","volume":"86","author":"Alculumbre","year":"2019","journal-title":"Semin Cell Dev Biol 10.1016\/J.SEMCDB.2018.02.014"},{"issue":"7756","key":"10.1016\/B978-0-12-822951-4.00042-4_bib42","first-page":"418","article-title":"MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs","volume":"569","author":"Gabisonia","year":"2019","journal-title":"Nature 10.1038\/s41586-019-1191-6"},{"issue":"12","key":"10.1016\/B978-0-12-822951-4.00042-4_bib43","first-page":"990","article-title":"Sympathetic reinnervation is required for mammalian cardiac regeneration","volume":"117","author":"White","year":"2015","journal-title":"Circ Res 10.1161\/CIRCRESAHA.115.307465"},{"issue":"4","key":"10.1016\/B978-0-12-822951-4.00042-4_bib44","first-page":"387","article-title":"Nerves regulate cardiomyocyte proliferation and heart regeneration","volume":"34","author":"Mahmoud","year":"2015","journal-title":"Dev Cell 10.1016\/J.DEVCEL.2015.06.017"},{"issue":"49","key":"10.1016\/B978-0-12-822951-4.00042-4_bib45","article-title":"Heart neurons use clock genes to control myocyte proliferation","volume":"7","author":"Tampakakis","year":"2021","journal-title":"Sci Adv 10.1126\/SCIADV.ABH4181"},{"issue":"9024","key":"10.1016\/B978-0-12-822951-4.00042-4_bib46","first-page":"370","article-title":"Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb","volume":"348","author":"Isner","year":"1996","journal-title":"Lancet 10.1016\/S0140-6736(96)03361-2"},{"issue":"5","key":"10.1016\/B978-0-12-822951-4.00042-4_bib47","first-page":"503","article-title":"Therapeutic angiogenesis for peripheral artery disease: lessons learned in translational science","volume":"2","author":"Iyer","year":"2017","journal-title":"JACC Basic Transl Sci 10.1016\/J.JACBTS.2017.07.012"},{"issue":"12","key":"10.1016\/B978-0-12-822951-4.00042-4_bib48","first-page":"3618","article-title":"Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: a multicentric, randomized trial","volume":"45","author":"Prasad","year":"2014","journal-title":"Stroke 10.1161\/STROKEAHA.114.007028"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib49","first-page":"88","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE Trial","volume":"168","author":"Perin","year":"2014","journal-title":"Am Heart J 10.1016\/J.AHJ.2014.03.022"},{"issue":"10","key":"10.1016\/B978-0-12-822951-4.00042-4_bib50","first-page":"1292","article-title":"Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells","volume":"109","author":"Rehman","year":"2004","journal-title":"Circulation 10.1161\/01.CIR.0000121425.42966"},{"issue":"7","key":"10.1016\/B978-0-12-822951-4.00042-4_bib51","first-page":"724","article-title":"Exosomes from human CD34+ stem cells mediate their proangiogenic paracrine activity","volume":"109","author":"Sahoo","year":"2011","journal-title":"Circ Res 10.1161\/CIRCRESAHA.111.253286"},{"issue":"7","key":"10.1016\/B978-0-12-822951-4.00042-4_bib52","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJM200102153440717","article-title":"Transplantation of a tissue-engineered pulmonary artery","volume":"344","author":"Shin\u2019oka","year":"2001","journal-title":"N Engl J Med 10.1056\/NEJM200102153440717"},{"issue":"10032","key":"10.1016\/B978-0-12-822951-4.00042-4_bib53","first-page":"2026","article-title":"Bioengineered human a cellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials","volume":"387","author":"Lawson","year":"2016","journal-title":"Lancet 10.1016\/S0140-6736(16)00557-2"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib54","first-page":"340","article-title":"Vascular tissue engineering: progress, challenges, and clinical promise","volume":"22","author":"Song","year":"2018","journal-title":"Cell Stem Cell 10.1016\/J.STEM.2018.02.009"},{"issue":"48","key":"10.1016\/B978-0-12-822951-4.00042-4_bib55","article-title":"Low-flow intussusception and metastable VEGFR2 signaling launch angiogenesis in ischemic muscle","volume":"7","author":"Arpino","year":"2021","journal-title":"Sci Adv 10.1126\/SCIADV.ABG9509"},{"issue":"6","key":"10.1016\/B978-0-12-822951-4.00042-4_bib56","first-page":"635","article-title":"Fabry disease: the current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs 10.1007\/S40265-021-01486-1"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib57","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis 10.1002\/JIMD.12080"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib58","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/jimd.12052","article-title":"Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease","volume":"42","author":"Hennermann","year":"2019","journal-title":"J Inherit Metab Dis 10.1002\/JIMD.12052"},{"issue":"13","key":"10.1016\/B978-0-12-822951-4.00042-4_bib59","first-page":"283","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med 10.21037\/ATM.2019.04.70"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib60","first-page":"59","article-title":"Discontinuation of enzyme replacement therapy in adults with Pompe disease: evaluating the European POmpe Consortium stop criteria","volume":"30","author":"van Kooten","year":"2020","journal-title":"Neuromuscul Disord 10.1016\/J.NMD.2019.11.007"},{"key":"10.1016\/B978-0-12-822951-4.00042-4_bib61","first-page":"199","article-title":"Enzyme replacement therapy can reverse pathogenic cascade in Pompe disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol Ther Methods Clin Dev 10.1016\/J.OMTM.2020.05.026"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib62","first-page":"1","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther 10.1038\/s41392-021-00487-6"},{"key":"10.1016\/B978-0-12-822951-4.00042-4_bib63","first-page":"276","article-title":"CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease","volume":"23","author":"Demirci","year":"2021","journal-title":"Mol Ther Methods Clin Dev. 10.1016\/J.OMTM.2021.09.010"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib64","first-page":"1","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun 10.1038\/s41467-021-21371-5"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib65","first-page":"S77","article-title":"A phase I\/II multicenter gene therapy clinical study for Fabry disease","volume":"129","author":"Hughes","year":"2020","journal-title":"Mol Genet Metab 10.1016\/J.YMGME.2019.11.186"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib66","first-page":"S77","article-title":"First-in-human study of a liver-directed AAV gene therapy (FLT190) in Fabry disease","volume":"129","author":"Hughes","year":"2020","journal-title":"Mol Genet Metab 10.1016\/J.YMGME.2019.11.188"},{"issue":"13","key":"10.1016\/B978-0-12-822951-4.00042-4_bib67","first-page":"287","article-title":"Progress and challenges of gene therapy for Pompe disease","volume":"7","author":"Ronzitti","year":"2019","journal-title":"Ann Transl Med 10.21037\/ATM.2019.04.67"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib68","first-page":"59","article-title":"Gene therapy for mucopolysaccharidoses","volume":"123","author":"Sawamoto","year":"2018","journal-title":"Mol Genet Metab 10.1016\/J.YMGME.2017.12.434"},{"issue":"7794","key":"10.1016\/B978-0-12-822951-4.00042-4_bib69","first-page":"229","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature 10.1038\/s41586-020-1978-5"},{"issue":"9","key":"10.1016\/B978-0-12-822951-4.00042-4_bib70","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat Rev Genet 10.1038\/nrg2842"},{"issue":"2","key":"10.1016\/B978-0-12-822951-4.00042-4_bib71","first-page":"143","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2010","journal-title":"Nat Biotechnol 10.1038\/nbt.1755"},{"issue":"7603","key":"10.1016\/B978-0-12-822951-4.00042-4_bib72","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature 10.1038\/NATURE17946"},{"issue":"6305","key":"10.1016\/B978-0-12-822951-4.00042-4_bib73","article-title":"Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems","volume":"353","author":"Nishida","year":"2016","journal-title":"Science 10.1126\/SCIENCE.AAF8729"},{"issue":"5","key":"10.1016\/B978-0-12-822951-4.00042-4_bib74","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/cvr\/cvz250","article-title":"CRISPR\/Cas9 gene-editing strategies in cardiovascular cells","volume":"116","author":"Vermersch","year":"2020","journal-title":"Cardiovasc Res 10.1093\/CVR\/CVZ250"},{"issue":"7668","key":"10.1016\/B978-0-12-822951-4.00042-4_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23305","article-title":"Correction of a pathogenic gene mutation in human embryos","volume":"548","author":"Ma","year":"2017","journal-title":"Nature 10.1038\/nature23305"},{"issue":"11","key":"10.1016\/B978-0-12-822951-4.00042-4_bib76","first-page":"2631","article-title":"Correction of the marfan syndrome pathogenic FBN1 mutation by base editing in human cells and heterozygous embryos","volume":"26","author":"Zeng","year":"2018","journal-title":"Mol Ther 10.1016\/J.YMTHE.2018.08.007"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med 10.1056\/NEJMOA2031054"},{"issue":"6","key":"10.1016\/B978-0-12-822951-4.00042-4_bib78","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med 10.1056\/NEJMOA2107454"},{"issue":"7859","key":"10.1016\/B978-0-12-822951-4.00042-4_bib79","first-page":"429","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature 10.1038\/s41586-021-03534-y"},{"issue":"10","key":"10.1016\/B978-0-12-822951-4.00042-4_bib80","first-page":"1513","article-title":"In utero CRISPR-mediated therapeutic editing of metabolic genes","volume":"24","author":"Rossidis","year":"2018","journal-title":"Nat Med 10.1038\/S41591-018-0184-6"},{"issue":"15\u201316","key":"10.1016\/B978-0-12-822951-4.00042-4_bib81","first-page":"794","article-title":"CRISPR\/Cas9 editing: sparking discussion on safety in light of the need for new therapeutics","volume":"31","author":"Carlaw","year":"2020","journal-title":"Hum Gene Ther 10.1089\/HUM.2020.111"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib82","first-page":"5","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener Dis Manag 10.2217\/NMT-2018-0033"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib83","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med 10.1056\/NEJMOA1716793"},{"issue":"1","key":"10.1016\/B978-0-12-822951-4.00042-4_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med 10.1056\/NEJMOA1609243"},{"issue":"11","key":"10.1016\/B978-0-12-822951-4.00042-4_bib85","first-page":"1","article-title":"RNA silencing in the management of dyslipidemias","volume":"23","author":"Henney","year":"2021","journal-title":"Curr Atheroscler Rep 10.1007\/S11883-021-00968-7"},{"issue":"593","key":"10.1016\/B978-0-12-822951-4.00042-4_bib86","article-title":"An oral antisense oligonucleotide for PCSK9 inhibition","volume":"13","author":"Gennemark","year":"2021","journal-title":"Sci Transl Med 10.1126\/SCITRANSLMED.ABE9117"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib87","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","article-title":"RNA therapeutics for cardiovascular disease","volume":"36","author":"Boada","year":"2021","journal-title":"Curr Opin Cardiol 10.1097\/HCO.0000000000000850"},{"issue":"3","key":"10.1016\/B978-0-12-822951-4.00042-4_bib93","first-page":"866","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol Ther March 10.1016\/j.ymthe.2022.11.017"},{"issue":"11","key":"10.1016\/B978-0-12-822951-4.00042-4_bib88","first-page":"1171","article-title":"Mavacamten: a novel small molecule modulator of \u03b2-cardiac myosin for treatment of hypertrophic cardiomyopathy","volume":"29","author":"Tower-Rader","year":"2020","journal-title":"Expert Opin Investig Drugs 10.1080\/13543784.2020.1821361"},{"issue":"10","key":"10.1016\/B978-0-12-822951-4.00042-4_bib89","article-title":"Current landscape of heart failure gene therapy","volume":"8","author":"Kieserman","year":"2019","journal-title":"J Am Heart Assoc 10.1161\/JAHA.119.012239"},{"issue":"622","key":"10.1016\/B978-0-12-822951-4.00042-4_bib90","article-title":"Therapeutic inhibition of RBM20 improves diastolic function in a murine heart failure model and human engineered heart tissue","volume":"13","author":"Radke","year":"2021","journal-title":"Sci Transl Med 10.1126\/scitranslmed.abe8952"},{"issue":"6576","key":"10.1016\/B978-0-12-822951-4.00042-4_bib91","first-page":"91","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science 10.1126\/SCIENCE.ABM0594"},{"issue":"7774","key":"10.1016\/B978-0-12-822951-4.00042-4_bib92","first-page":"430","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature 10.1038\/s41586-019-1546-z"}],"container-title":["Genomic and Molecular Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128229514000424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780128229514000424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:56:10Z","timestamp":1756486570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780128229514000424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780128229514"],"references-count":93,"URL":"https:\/\/doi.org\/10.1016\/b978-0-12-822951-4.00042-4","relation":{},"subject":[],"published":{"date-parts":[[2024]]}}}